 | Increase Productivity, Reduce R&D Spending
This webinar presents new concepts to improve productivity in the lab and discusses the challenges of implementing new technologies in the organic synthesis lab, their acceptance by chemists, and how a sustainable increase of productivity can be achieved. Register for the webinar. |
 - Idenix candidate for hepatitis C does well in early data
Idenix Pharmaceuticals reported interim data from a Phase IIb trial showing that its lead hepatitis C agent reduced viral load to an undetectable level after 28 days in 73% of patients given a 100-milligram dose and 63% of those who took 50 milligrams. "In 2012, we will build on this progress and believe we are well positioned to play a major role in treating [hepatitis C virus] patients for the foreseeable future," said CEO Ron Renaud. Idenix also began an early-stage study of nucleotide inhibitor IDX719 and chose two similar compounds as potential drug candidates. The Wall Street Journal (1/9)       - Pfizer partners with SFJ for cancer drug trial in Asia
Pfizer and SFJ Pharma agreed to jointly conduct a Phase III trial in Asia evaluating the former's experimental drug axitinib as an adjuvant treatment for patients at great risk of recurrent renal cell carcinoma after undergoing nephrectomy. The deal entitles SFJ to milestone and earn-out payments upon approval of the drug, in exchange for funding the trial and managing clinical development needed for review of axitinib. Genetic Engineering & Biotechnology News (1/9) - Stem cells among year's top stories in myeloma research
Advances in stem cell treatments were among the most significant news in myeloma research in 2011, according to the Myeloma Beacon. In the past year, researchers reported promising results from a Phase III trial of stem cell transplantation, confirmed transplantation's long-term disease-free outcomes and found comparable benefits for early and delayed transplantation in newly diagnosed patients. MyelomaBeacon.com (1/6)  | Company & Financial News |  |  | | - Novartis looks to acquire assets worth as much as $3 billion
Novartis is willing to spend $2 billion to $3 billion each on "bolt-on" acquisitions that would complement the product pipeline of the drugmaker and subsidiary Alcon, CEO Joseph Jimenez said. The firm also wants to achieve greater worldwide presence by expanding in nonprescription and animal-health products, Jimenez said. Bloomberg (1/9) | Global Developments | | | | - U.K., Norway collaborate on biotech projects
The U.K. Technology Strategy Board and Innovation Norway committed a total of $3.4 million to fund nine biotechnology and biorefining projects to help reduce oil dependence. The projects will help businesses "develop early-stage biotechnology projects into pilots and to turn pilots into commercially viable processes," according to TSB innovation programs director David Bott. BusinessGreen (U.K.) (1/10)
| Food & Agriculture | | | | - Monsanto, soon to market 14 technologies, reports earnings
Monsanto announced that 14 projects in its pipeline are nearing commercialization including a drought-resistant corn, a disease-tolerant pepper, a corn with better pest resistance, and a new Roundup formulation combined with existing herbicide dicamba. The company reported higher-than-expected profits for the past quarter, mainly driven by strong sales of biotech seeds in Latin America. St. Louis Post-Dispatch (1/6) | Industrial & Environmental | | | | - Refiners face up to $6.8M in fines for failure to use cellulosic fuels
Refiners face about $6.8 million in fines for failing to meet the 2011 federal mandate on cellulosic fuels, which were practically unavailable in the market last year. "From a taxpayer/consumer standpoint, it doesn't seem to make a lot of sense that we would require blenders to pay fines or fees or whatever for stuff that literally isn't available," said retired Vice Admiral Dennis V. McGinn of the American Council on Renewable Energy. McGinn, however, said that mandating the use of cellulosic fuels "is the right thing to do" from a national security and economic standpoint. The New York Times (tiered subscription model) (1/9) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the monthly BIOtechNOW e-newsletter.
| SmartQuote | | | |  | The river flows at its own sweet will, but the flood is bound in the two banks. If it were not thus bound, its freedom would be wasted."
--Vinoba Bhave,
Indian leader  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, January 09, 2012
- Friday, January 06, 2012
- Thursday, January 05, 2012
- Wednesday, January 04, 2012
- Tuesday, January 03, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment